Annovis Bio's Participation in Key Neuroscience Conference

Annovis Bio to Participate in Renowned Neuroscience Event

MALVERN, Pa. — Annovis Bio Inc. (NYSE: ANVS), a prominent clinical-stage biopharmaceutical company focused on pioneering innovative therapies for neurodegenerative diseases, is thrilled to announce its participation in the upcoming AD/PD™ 2025 conference.

Highlights from the Conference

This prestigious event, set to take place in Vienna from April 1-5, will see Annovis showcasing vital research findings related to Alzheimer's disease (AD) and Parkinson's disease (PD), two conditions that greatly impact millions worldwide. During the conference, Annovis will present data from its latest clinical studies, which underscore the potential of its lead product, buntanetap, in effectively treating these conditions.

Presentations on Groundbreaking Research

The company has scheduled two significant presentations and a forum discussion at the conference:

First Presentation: Buntanetap Improves Early Parkinson's Patients' Cognition and Motor Functions in a Phase 3 Study
Date: April 1
Time: 2:45 – 3:00 PM CET
Presenter: Maria Maccecchini, Ph.D., Founder and CEO

Second Presentation: APOE4 and Buntanetap in Phase II/III Alzheimer’s Patients
Date: April 2
Time: 9:40 – 9:55 AM CET
Presenter: Cheng Fang, Ph.D., SVP, Research and Development

Additionally, Annovis will participate in a forum discussion titled Novel Approaches to Accelerate Development of Biomarkers, Imaging, and Therapy of Alpha-Synuclein, LRRK2, and GBA Pathologies Linked to PD, LBD, and MSA on April 4 from 4:20 to 5:20 PM CET, featuring discussion led by Dr. Maccecchini.

Significance of the AD/PD™ Conference

The AD/PD™ conference is a crucial platform that brings together leading experts from around the world to discuss recent advancements in the fields of Alzheimer's and Parkinson's research. This year's conference will highlight the latest breakthroughs in drug development, early diagnosis techniques, and translational research, allowing researchers and clinicians to engage with pivotal ideas and collaborations that may shape the future of treatment in neurodegenerative diseases.

About Annovis Bio

Based in Malvern, Pennsylvania, Annovis is on a mission to tackle the challenges of neurodegeneration in diseases such as Alzheimer's and Parkinson's. The company is committed to innovating therapies that aim to enhance not just the clinical outcomes for patients but also their quality of life.

Staying Informed

Interested individuals can learn more by visiting Annovis's website, where updates and more information regarding their innovative approaches and ongoing trials can be found.

Contact Details for Inquiries

For further inquiries, reach out to:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
Website: www.annovisbio.com

Investor Communications

Investors and shareholders are encouraged to register for email alerts on press releases and industry updates, ensuring they remain informed on developments within the company and the field.

Frequently Asked Questions

What is Annovis Bio focused on?

Annovis Bio concentrates on developing innovative therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's diseases.

When will Annovis present at the conference?

Annovis will hold its first presentation on April 1 and a second on April 2 at the AD/PD 2025 conference.

Who are the presenters from Annovis Bio?

Maria Maccecchini, Ph.D., and Cheng Fang, Ph.D., will be giving the key presentations during the conference.

Where is the conference being held?

The AD/PD 2025 conference is set to take place in Vienna.

How can I stay updated with Annovis Bio news?

Visit the company's website and register for email alerts to stay informed about ongoing research and company news.

About The Author

Olivia Taylor here, a 26-year-old writer and financial advisor. After earning a degree in finance, I worked in the sector for years. I've always loved numbers and had a talent for simplifying difficult financial ideas so that anyone could understand. I wrote my first book because of this passion; it helps readers take charge of their financial futures by fusing real-life stories with useful financial advice.

Whether they are just beginning their careers, preparing for significant life events, or seeking to invest wisely, my goal with my writing is to enable people to make educated financial decisions. The foundation of my work is the conviction that security and freedom of the individual are largely determined by financial literacy. To further financial education, I run workshops and frequently write for financial blogs in addition to my books.

I like to travel, experience other cultures, and find inspiration in daily life when I'm not writing or examining market trends. My passion is utilizing sound financial practices to help people reach their financial objectives and lead the best lives possible.

Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.